Drug Eruption and Interactions - PHARMACEUTICAL REVIEW
Drug Eruption and Interactions - PHARMACEUTICAL REVIEW Drug Eruption and Interactions - PHARMACEUTICAL REVIEW
Hair Hair – alopecia (>2%) Nails Nails – changes (>2%) Eyes Xerophthalmia Other Anaphylactoid reactions/Anaphylaxis (2005): Rauschka H+, Neurology 64(8), 1481 Chills (4%) Cough (>2%) Embolia cutis medicamentosa (Nicolau syndrome) (2003): Gaudez C+, Rev Neurol (Paris) 159(5), 571 Facial numbness Gynecomastia Infections (50%) Injection-site abscess Injection-site atrophy Injection-site bleeding (5%) Injection-site ecchymoses (>2%) Injection-site edema Injection-site erythema (66%) (2005): Nolden S+, Mult Scler 11(2), 245 (2001): Ziemssen T+, Drug Saf 24(13), 979 Injection-site fibrosis Injection-site hematoma Injection-site hypersensitivity Injection-site induration (13%) (2005): Nolden S+, Mult Scler 11(2), 245 (2004): Soos N+, Am J Clin Dermatol 5(5), 357 (2001): Ziemssen T+, Drug Saf 24(13), 979 Injection-site inflammation (49%) (2001): Ziemssen T+, Drug Saf 24(13), 979 Injection-site lipoatrophy (2004): Edgar CM+, Can J Neurol Sci 31(1), 58 (45%) (2004): Soos N+, Am J Clin Dermatol 5(5), 357 Injection-site pain (73%) (2005): Nolden S+, Mult Scler 11(2), 245 Injection-site panniculitis (2004): Soos N+, Am J Clin Dermatol 5(5), 357 Injection-site pigmentation Injection-site pruritus (40%) (2005): Nolden S+, Mult Scler 11(2), 245 Injection-site reactions (6–67%) (2006): Gordon PH+, Neurology 66(7), 1117 (2005): Fiore AP+, Arq Neuropsiquiatr 63(3B), 738 (2004): Prescrire Int 13(69), 10 (2002): Flechter S+, JNeurolSci197(1), 51 (67%) (2002): Ziemssen T+, Nervenarzt 73(4), 321 Injection-site urticaria (5%) Lipoatrophy (2001): Hwang L+, Cutis 68(4), 287 (1999): Drago F+, Arch Dermatol 135(10), 1277 (localized) Lipomatosis Lymphedema Moon face Myalgia/Myositis/Myopathy/Myotoxicity (>2%) Pain (28%) Panniculitis (2006): Soares Almeida LM+, JAmAcadDermatol55(6), 968 Serum sickness Tumors GLIMEPIRIDE* Trade name: Amaryl (Sanofi-Aventis) Indications: Non-insulin dependent diabetes type ll Category: Sulfonylurea Half-life: 5–9 hours Reactions Skin Allergic reactions (sic) (
254 GLIPIZIDE Purpura Rash (sic) (1–10%) Stevens–Johnson syndrome (2006): Cheng JB+, Dermatitis 17(1), 36 Urticaria (1–10%) Mucosal Oral lichen planus (1990): Lamey PJ+, Oral Surg Oral Med Oral Path 70, 184 Other Myalgia/Myositis/Myopathy/Myotoxicity (
- Page 278 and 279: Stevens-Johnson syndrome (
- Page 280 and 281: Ocular pruritus (1-10%) Other Cough
- Page 282 and 283: (2002): Bohm M+, Drug Saf 25(8), 59
- Page 284 and 285: Pustules (1993): Manu Shah R+, Eur
- Page 286 and 287: ESTAZOLAM Trade names: Domnamid; Es
- Page 288 and 289: Allergic reactions (sic) Cellulitis
- Page 290 and 291: Exanthems Photosensitivity Purpura
- Page 292 and 293: Other Anticonvulsant hypersensitivi
- Page 294 and 295: ETORICOXIB Trade names: Algix; Arco
- Page 296 and 297: Purpura (1996): Kallal SM+, West J
- Page 298 and 299: (1980): Couzigou P+, Therapie 35(3)
- Page 300 and 301: FINASTERIDE Trade names: Pro-Cure;
- Page 302 and 303: (1991): Abbott M+, Lancet 2, 633 Bu
- Page 304 and 305: FLUOCINOLONE Trade names: Capex (Ga
- Page 306 and 307: (2003): Salim A+, Br J Dermatol 148
- Page 308 and 309: Erythema multiforme (1985): Wernick
- Page 310 and 311: Injection-site reactions Rhabdomyol
- Page 312 and 313: Toxic epidermal necrolysis Urticari
- Page 314 and 315: Reactions Skin Angioedema Erythema
- Page 316 and 317: Reactions Skin Acne (
- Page 318 and 319: Thrombophlebitis *Note: Furosemide
- Page 320 and 321: GANCICLOVIR Trade names: Cymevan; C
- Page 322 and 323: (2002): Baselga J+, J Clin Oncol 20
- Page 324 and 325: (2003): D’Alessandro V+, Clin Ter
- Page 326 and 327: (1996): Merlob P+, Cutis 57, 429 (n
- Page 330 and 331: GLYBURIDE Synonyms: glibenclamide;
- Page 332 and 333: (1982): Bailin PL+, Clin Rheum Dis
- Page 334 and 335: Acne (1996): Lee PK+, JAmAcadDermat
- Page 336 and 337: (2006): Bonkovsky HL, AnnInternMed1
- Page 338 and 339: Peripheral edema (>10%) Purpura Urt
- Page 340 and 341: (1984): Binder RL+, J Clin Psychiat
- Page 342 and 343: HEPARIN Trade names: Calcilean; Cal
- Page 344 and 345: (1990): Rogerson SJ+, BMJ 301, 345
- Page 346 and 347: (1991): Vitris M+, Dakar Med 36(1),
- Page 348 and 349: Other Anaphylactoid reactions/Anaph
- Page 350 and 351: Exanthems Exfoliative dermatitis Fi
- Page 352 and 353: HYDROMORPHONE Trade names: Dilaudid
- Page 354 and 355: (1994): Perrot JL+, Ann Dermatol Ve
- Page 356 and 357: Edema (
- Page 358 and 359: (1994): Halpern SM, Arch Dermatol 1
- Page 360 and 361: Mucosal Oral lesions Sialorrhea (
- Page 362 and 363: IMIGLUCERASE Trade name: Cerezyme (
- Page 364 and 365: (2001): Fife KH+, Sex Transm Dis 28
- Page 366 and 367: Herpes simplex (
- Page 368 and 369: (2004): Scheinfeld N, J Drugs Derma
- Page 370 and 371: (2000): Poole PJ+, Cochrane Databas
- Page 372 and 373: Injection-site pain (2006): Moyes V
- Page 374 and 375: (2002): Tothova E+, Neoplasma 49(2)
- Page 376 and 377: (1995): Shinohara K, NEnglJMed333,
Hair<br />
Hair – alopecia (>2%)<br />
Nails<br />
Nails – changes (>2%)<br />
Eyes<br />
Xerophthalmia<br />
Other<br />
Anaphylactoid reactions/Anaphylaxis<br />
(2005): Rauschka H+, Neurology 64(8), 1481<br />
Chills (4%)<br />
Cough (>2%)<br />
Embolia cutis medicamentosa (Nicolau syndrome)<br />
(2003): Gaudez C+, Rev Neurol (Paris) 159(5), 571<br />
Facial numbness<br />
Gynecomastia<br />
Infections (50%)<br />
Injection-site abscess<br />
Injection-site atrophy<br />
Injection-site bleeding (5%)<br />
Injection-site ecchymoses (>2%)<br />
Injection-site edema<br />
Injection-site erythema (66%)<br />
(2005): Nolden S+, Mult Scler 11(2), 245<br />
(2001): Ziemssen T+, <strong>Drug</strong> Saf 24(13), 979<br />
Injection-site fibrosis<br />
Injection-site hematoma<br />
Injection-site hypersensitivity<br />
Injection-site induration (13%)<br />
(2005): Nolden S+, Mult Scler 11(2), 245<br />
(2004): Soos N+, Am J Clin Dermatol 5(5), 357<br />
(2001): Ziemssen T+, <strong>Drug</strong> Saf 24(13), 979<br />
Injection-site inflammation (49%)<br />
(2001): Ziemssen T+, <strong>Drug</strong> Saf 24(13), 979<br />
Injection-site lipoatrophy<br />
(2004): Edgar CM+, Can J Neurol Sci 31(1), 58 (45%)<br />
(2004): Soos N+, Am J Clin Dermatol 5(5), 357<br />
Injection-site pain (73%)<br />
(2005): Nolden S+, Mult Scler 11(2), 245<br />
Injection-site panniculitis<br />
(2004): Soos N+, Am J Clin Dermatol 5(5), 357<br />
Injection-site pigmentation<br />
Injection-site pruritus (40%)<br />
(2005): Nolden S+, Mult Scler 11(2), 245<br />
Injection-site reactions (6–67%)<br />
(2006): Gordon PH+, Neurology 66(7), 1117<br />
(2005): Fiore AP+, Arq Neuropsiquiatr 63(3B), 738<br />
(2004): Prescrire Int 13(69), 10<br />
(2002): Flechter S+, JNeurolSci197(1), 51 (67%)<br />
(2002): Ziemssen T+, Nervenarzt 73(4), 321<br />
Injection-site urticaria (5%)<br />
Lipoatrophy<br />
(2001): Hwang L+, Cutis 68(4), 287<br />
(1999): Drago F+, Arch Dermatol 135(10), 1277 (localized)<br />
Lipomatosis<br />
Lymphedema<br />
Moon face<br />
Myalgia/Myositis/Myopathy/Myotoxicity (>2%)<br />
Pain (28%)<br />
Panniculitis<br />
(2006): Soares Almeida LM+, JAmAcadDermatol55(6), 968<br />
Serum sickness<br />
Tumors<br />
GLIMEPIRIDE*<br />
Trade name: Amaryl (Sanofi-Aventis)<br />
Indications: Non-insulin dependent diabetes type ll<br />
Category: Sulfonylurea<br />
Half-life: 5–9 hours<br />
Reactions<br />
Skin<br />
Allergic reactions (sic) (
Change language